Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel on September 27th-28th 2016, and will be presenting a company update at 14.10h on September 27th in the Lima room. The Biotech in Europe Forum is expected to attract more than 600 attendees this year.
Dr Ribeiro said: “ProAxsis continues to make significant progress, with its ProteaseTag® Active Neutrophil Elastase Immunoassay selected for use in several pharmaceutical clinical trials, and further product launches planned in the near future. Forums such as Biotech in Europe provide ongoing opportunities for us to interact with potential partners and the life sciences community in general.”
Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the company’s proprietary ProteaseTag® technology, can be directed to info@77.104.171.207.
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
Related News
ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st …
ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes …